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Abstract Purpose: We have shown previously that
carbogen (95% 02, 5% CO2) breathing by rodents can
increase uptake of anticancer drugs into tumours. The
aim of this study was to extend these observations to
other rodent models using the anticancer drug 5-ﬂuo-
rouracil (5FU). 5FU pharmacokinetics in tumour and
plasma and physiological eﬀects on the tumour by
carbogen were investigated to determine the locus of
carbogen action on augmenting tumour uptake of 5FU.
Methods: Two diﬀerent tumour models were used, rat
GH3 prolactinomas xenografted s.c. into nude mice and
rat H9618a hepatomas grown s.c. in syngeneic Buﬀalo
rats. Uptake and metabolism of 5FU in both tumour
models with or without host carbogen breathing was
studied non-invasively using ﬂuorine-19 magnetic reso-
nance spectroscopy (19F-MRS), while plasma samples
from Buﬀalo rats were used to construct a NONMEM
pharmacokinetic model. Physiological eﬀects of carbo-
gen on tumours were studied using 31P-MRS for energy
status (NTP/Pi) and pH, and gradient-recalled echo
magnetic resonance imaging (GRE-MRI) for blood ﬂow
and oxygenation. Results: In both tumour models, car-
bogan-induced GRE-MRI signal intensity increases of
60% consistent with an increase in tumour blood
oxygenation and/or ﬂow. In GH3 xenografts, 19F-MRS
showed that carbogen had no signiﬁcant eﬀect on 5FU
uptake and metabolism by the tumours, and 31P-MRS
showed there was no change in the NTP/Pi ratio. In
H9618a hepatomas, 19F-MRS showed that carbogen
had no eﬀect on tumour 5FU uptake but signiﬁcantly
(p=0.0003) increased 5FU elimination from the tumour
(i.e. decreased the t1/2) and signiﬁcantly (p=0.029) in-
creased (53%) the rate of metabolism to cytotoxic ﬂu-
oronucleotides (FNuct). The pharmacokinetic analysis
showed that carbogen increased the rate of tumour up-
take of 5FU from the plasma but also increased the rate
of removal. 31P-MRS showed there were signiﬁcant
(p £ 0.02) increases in the hepatoma NTP/Pi ratio of
49% and transmembrane pH gradient of 0.11 units.
Conclusions: We suggest that carbogen can transiently
increase tumour blood ﬂow, but this eﬀect alone may
not increase uptake of anticancer drugs without a sec-
ondary mechanism operating. In the case of the hepa-
toma, the increase in tumour energy status and pH
gradient may be suﬃcient to augment 5FU metabolism
to cytotoxic FNuct, while in the GH3 xenografts this
was not the case. Thus carbogen breathing does not
universally lead to increased uptake of anticancer drugs.
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Abbreviations AUC: Area under the concentration–time
curve Æ Cmax: Maximum value Æ DHFU: Dihydro-
ﬂuorouracil Æ 5FU: 5-Fluorouracil Æ FTP: 5-
Fluorotryptophan Æ FBal: 5-Fluoro-b-alanine Æ FUPA:
5-Fluoro-b-ureidopropionic acid Æ FNuct:
5-Fluoronucleotides Æ FCat: Fluorocatabolites Æ GRE:
Gradient recalled-echo Æ MRS: Magnetic resonance
spectroscopy Æ NaF: Sodium ﬂuoride Æ DpH: pH
gradient across the plasma membrane Æ t1/2: 5FU
elimination half-life Æ V1: 5FU in the body Æ V2: 5FU in
the tumour Æ CL10: 5FU elimination from the body Æ
CLd: Bi-directional clearance of 5FU (body and
tumour) Æ CLm: Metabolic clearance of 5FU in the
tumour
Introduction
A major factor in the relatively low success of systemic
anticancer chemotherapy is inadequate drug delivery to
the solid tumour. This is partly due to the poor vascular
supply of solid tumours which additionally leads to
hypoxic regions, as well as the high hydrostatic pressure
in the tumour extracellular space [5]. There is thus a
clinical need to improve drug delivery for both new and
old chemotherapeutics for the treatment of the majority
of solid tumours.
Breathing carbogen (95% O2, 5% CO2) by rats and
mice has been shown to increase the uptake of anti-
cancer drugs by solid tumours [13, 19, 31, 32]. In the
GH3 prolactinoma grown in syngeneic rats, carbogen
increased the maximum concentration of ifosfamide
(Cmax) in the tumour by 60% and although time for
drug elimination (t1/2) was unchanged, the area under
the concentration–time curve (AUC) was signiﬁcantly
increased. Uptake and retention of ifosfamide by the
liver [31] and other normal tissues were unchanged [29]
showing that the eﬀect of carbogen was selective for
tumours. In mouse RIF-1 ﬁbrosarcomas grown in
syngeneic mice, carbogen decreased the rate of elimi-
nation of 5-ﬂuorouracil (5FU) by 30%, and caused
increased 5FU uptake and activation, although the
latter eﬀect only occurred in tumours which were
considered hypoxic due to high retention of a nitro-
imadazole [19]. In both these animal tumour models,
carbogen augmented drug-induced growth inhibition
of the tumour. The mechanism of these eﬀects is
complex, but a major factor is likely to be a carbogen-
induced transient increase in blood ﬂow and/or blood
volume to all or part of the tumour. However, other
changes in rodent tumours also occur in response to
carbogen breathing which include decreases in extra-
cellular pH [19, 37] and increases in tissue oxygenation
[1, 8, 30], and they may also play a role in the
increased retention of 5FU by tumours. 5FU is a
pro-drug which is metabolised in tissues to 5-ﬂuoro-
nucleotides (FNuct), or degraded (mostly in the liver)
to non-cytotoxic catabolites such as ﬂuoro-b-alanine.
Increased tumour concentrations of 5FU are strongly
associated with improved response both in pre-clinical
and clinical models [17–19, 24, 26, 35]. Thus, a
mechanism that leads to increased uptake and/or
retention of 5FU by tumours will lead to increased
tumour cell kill.
Gradient-recalled echo (GRE) imaging of GH3
tumours grown in rats showed that carbogen caused a
rapid and completely reversible twofold increase in
image intensity [27], a phenomenon that reﬂects
predominantly an increase in tumour blood oxygena-
tion, as well as heterogeneous increases in tumour blood
ﬂow [10, 30]. Investigation of ﬁve other solid tumour
models grown in rodents showed that carbogen induced
similar or smaller increases in three of these models,
namely, the same GH3 tumour xenografted into nude
mice, the Morris hepatoma, H9618a transplanted into
syngeneic rats and a chemically induced rat mammary
adenocarcinoma. However, in the two other models, the
RIF-1 ﬁbrosarcoma grown in syngeneic mice and the
human HT29 adenocarcinoma xenografted in nude
mice, transient decreases in image intensity were ob-
served [28]. In human tumour studies, the responses to
carbogen were also variable. Over 70% of the tumours
studied showed an increase in signal intensity, with a
range of increases from 4% to 80% [7, 38]. A recent
report measured the eﬀect of carbogen on the oxygen-
ation of RIF-1 tumours and demonstrated considerable
variability in the changes in pO2 ranging from no eﬀect
(4/10) to increases of 20–50% (4/10) to >8-fold
increases (2/10) [12]. Taken together, all these experi-
ments suggest that the eﬀect of carbogen breathing on
anticancer drug uptake by tumours could also be very
variable too.
In order to investigate further the inﬂuence of
carbogen on 5FU pharmacokinetics and tumour
physiology, we have measured changes in tumour 5FU
uptake and metabolism and GRE-image intensity in
response to carbogen in the Morris rat hepatoma
H9618a and in the GH3 prolactinoma xenografted into
nude mice. The H9618a hepatoma was selected because
we have shown there is a large physiological response
to carbogen: the ATP/Pi ratio and pO2 both increase
[37], and in the GH3 tumour we had already shown
that carbogen could increase the initial uptake of the
anticancer drug ifosfamide [31]. In the rat hepatoma,
5FU uptake and metabolism in the tumour was mod-
elled pharmacokinetically to determine the locus of
carbogen action. The results show that carbogen can
rapidly increase drug uptake from the plasma, but
simultaneously increases drug elimination from the
tumour tissue space back to plasma. Thus, for carbo-
gen to increase tumour uptake of 5FU, a secondary
mechanism may be necessary, involving for example a
decrease in tumour pH. Such a change was observed in
hypoxic RIF-1 tumours [19] and this or other changes
may be required in order to obtain therapeutic beneﬁt
from carbogen breathing.
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Methods
Materials 5FU was obtained from David Bull Labo-
ratories (Warwick, UK) as a saline solution of 25 mg/
ml. Sodium ﬂuoride (NaF), 5-ﬂuorotryptophan (FTP)
and 3-aminopropylphosphonate (3-APP) were obtained
from Sigma (Poole, Dorset, UK). Carbogen gas (95%
O2, 5% CO2) was obtained from BOC Ltd (Guildford,
Surrey, UK).
Animals and tumour models Rat prolactinoma (GH3)
tumours in MF1 nude mice and rat hepatoma
(H9168a) tumours in Buﬀalo rats were grown s.c. in
the ﬂanks of animals as previously described [28, 36].
Tumour volume was determined by measuring three
orthogonal dimensions and using the formula (p/
6)·l·w·h, and they were used for studies when 0.5–1 g
(mice) or 2–8 g (rats). All MR studies utilised a Varian
200/330 4.7-T horizontal bore spectrometer with ani-
mals positioned so that tumours hung freely into a
surface coil. Body temperature was maintained at 36–
37C with a warmed water pad.
Protocol used for 19F and 31P-MRS studies of mice
bearing GH3 xenografts MF1 nude mice (ca. 30 g) were
anaesthetised with Hypnorm/Hypnovel (0.3 ml i.p. of
12.5 mg/kg midazolam, 25 mg/kg ﬂuanisone and
0.8 mg/kg fentanyl citrate in water) and tumours sus-
pended into an 18 mm surface coil tunable to both 31P
and 19F. The coil was tuned to 1H so that the shimming
was performed over the same volume as the spectros-
copy. The experimental set-up for this tumour model was
as previously described [19] and included a bulb con-
taining 100 ll of 15 mM FTP (1,500 nmoles) positioned
5 mm under the coil as an external 19F standard. The
animals were ﬁtted with a nose-piece equipped with a
scavenger so that they could breathe air or carbogen
which was supplied at a rate of 2 l/min. First, while the
animals breathed air, a 5 min 31P-spectrum (246·1.2 s
transients using a 90 ﬂip-angle with a spectral width of
8 kHz) was obtained. The gas supply was then switched
to carbogen and another 5 min 31P spectrum acquired.
After 19 min of carbogen breathing, 5FU was injected
i.p. as a 130 mg/kg/4 ml bolus of 1 min. It is known that
a bolus injection i.p. of 125 mg/kg 5FU in 30 g mice
leads to a rapid entrance of 5FU into the blood with a
Cmax at 4–5 min [9]. The gas supply was then returned to
air for the remainder of the experiment while 11·10 min
consecutive 19F spectra were acquired (1,200·0.5 s
transients using a 45 ﬂip-angle and a spectral width of
25 kHz), i.e. protocol 1 (see Fig. 1). Finally, a third
5 min 31P spectrum was acquired. Spectra were analysed
as previously described using VARPRO (31P) or FIT-
SPEC (19F) [19], with the exception that in this report the
19F-data are presented as nmoles/g of tumour. Correc-
tions were made for the saturation of the signals from the
FTP external standard and from 5FU and its metabolites
assuming that for all tumours, the T1, coil-loading and
ﬂip-angle were constant. Under these conditions, the
correction factors were 5.0, 2.2, 1.8 and 2.5 for FTP,
5FU, FNuct and FCat (FUPA + FBal), respectively;
very similar to those previously described [16].
Protocols used for 19F-MRS studies of rats bearing
H9168a hepatomas Rats (ca. 200 g) were anaesthetised
with an i.p. injection of ca. 0.2 ml Sagatal (50 mg/kg)
and tumours suspended into a 20 mm surface coil tuned
to 19F with a bulb containing 16 ll of 500 mM NaF
(8,000 nmoles) positioned 5 mm under the coil as an
external 19F standard. Animals breathed air or carbogen
as described above. Two diﬀerent carbogen-breathing
protocols were used (Fig. 1). In protocol 2a, the gas
supply was switched from air to carbogen and after
19 min, 5FU was injected i.v. as a 100 mg/kg bolus of
1 min and the gas supply returned to air for the
remainder of the experiment (total carbogen time was
20 min and thus equivalent to protocol 1 for GH3 xe-
nografts). Consecutive 19F spectra of 11 (or in some
cases 12) · 10 min were acquired (1,200·0.5 s transients
using a 45 ﬂip-angle and a spectral width of 25 kHz)
immediately following 5FU injection. Protocol 2b was
the same as protocol 2a, but after the same 5FU dose,
the carbogen supply was maintained for a further
10 min before the gas supply was returned to air for the
remainder of the experiment (total carbogen time
30 min). Consecutive 19F spectra (11·10 min) were then
acquired immediately after 5FU injection. Spectra were
Fig. 1 Protocols for carbogen breathing in the 19F-MRS studies.
Gases were supplied at a rate of 2 l/min. 5FU (130 mg/kg/4 ml)
was administered as an i.v. bolus of 1 min (at t=19–20 min). MRS
was performed as described in ‘‘Methods’’
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analysed as described above except that in this case the
correction factors were 1.2, 2.1, 2.0, 2.6 and 1.0 for NaF,
5FU, FNuct, FCat (FUPA + FBal) and DHFU,
respectively, again making the assumption that for all
tumours, the T1, coil-loading and ﬂip-angle were con-
stant.
Gradient-recalled echo 1H-imaging of GH3 xeno-
grafts A separate cohort of six mice bearing GH3 tu-
mours of 0.8–1.2 g were examined using the double-
tuned 31P/19F surface coil and set-up described above.
Consecutive GRE-images, each of 4 min, were obtained
as previously described [19] using a 45 ﬂip-angle with
TR=80 ms and TE=20 ms. Animals breathed air for a
16 min which was then switched to carbogen breathing
for 16 min, before returning to air breathing for a ﬁnal
period of 16 min.
GRE-1H-imaging interleaved with 31P-spectroscopy of
H9168a tumours A 2-turn, 2 cm 1H/31P surface coil
was used to perform GRE-imaging as described above,
except that every 8 min during the periods of air or
carbogen breathing, 4 min non-localised 31P-spectra
were also obtained before returning to image acquisi-
tion. The prior injection of 3-APP (11 mmol/kg i.p.) as
previously described [23] allowed simultaneous mea-
surements of the eﬀect of carbogen on tumour intra-
cellular and extracellular pH (pHi and pHe, respectively)
and b-NTP/Pi ratios. Animals breathed carbogen for
20 min, and after switching to air, images were acquired
for a further 20 min followed by a ﬁnal 31P spectrum.
5FU pharmacokinetics in plasma Eight Buﬀalo rats
were anaesthetised as described above and 5FU injected
as an i.v. bolus of 100 mg/kg/4 ml via the tail vein.
Blood samples of 50–100 ll were taken between 5 min
and 60 min post-injection for four animals, and between
10 min and 90 min for the other four animals. The
samples were placed in cold heparinised tubes, centri-
fuged and the plasma supernatant stored at 20C.
Plasma levels of 5FU were determined by gas chroma-
tography linked to mass spectrometry (GC–MS) [24]
(see Table 1).
Pharmacokinetic modelling A pharmacokinetic model
was ﬁtted to the data on 5FU in plasma and 5FU and
FNuct in hepatomas in order to distinguish the eﬀect of
carbogen on kinetics in plasma from that on kinetics in
tumour, and in order to derive the total amount of
FNuct formed. Mixed-eﬀects modelling [34] was applied
using the program system NONMEM [3]. A similar
pharmacokinetic model has been described [25].
5FU kinetics in plasma were described with a linear
one-compartment model (Fig. 2, left box). The volume
of the central compartment, V1 (total body, including
plasma but excluding tumour), and the elimination
clearance from the central compartment, CL10, were
assumed to be related to body weight according to
established allometric relationships [2, 40].
V1;i ¼ V1 BWi
0:215 kg
 
ð1Þ
CL10;i ¼ CL10 BWi
0:215 kg
 0:75
ð2Þ
where V1,i and CL10,i are the expected values of V1 and
CL10, respectively, in an animal with body weight =
0.215 kg, i=1,. . ., total number of animals, and BWi is
individual body weight in kg (0.215 kg was the median
body weight in this group of rats). Inter-individual
random variation was modelled using
Table 1 Concentrations of 5FU in rat plasma from 5 min to
90 min in eight diﬀerent rats
Rat number Sample time (min) Concentration 5FU (lM)
1 13, 37, 91 1,451, 188, 15
2 5, 13, 56 1,928, 1,003, 100
3 11, 20, 81 688, 491, 23
4 9.5, 30, 93 819, 465, 120
5 5, 20, 60.5 790, 693, 155
6 5.5, 19, 61.5 800, 528, 135
7 5.5, 20, 60 975, 525, 133
8 10.5, 20, 90 734, 514, 18
Non-tumour-bearing Buﬀalo rats were injected with 100 mg/kg/
4 ml of 5FU and blood samples (50–100 ll) were taken from the
anaesthetised animals and analysed as described in ‘‘Methods’’
Fig. 2 Linear pharmacokinetic model for 5FU in Buﬀalo rats
bearing H9168a hepatomas. 5FU input, I, goes into compartment 1
with volume V1 from where it is eliminated via the elimination
clearance, CL10. 5FU exchanges between compartment 1 and
tumour via the bi-directional distribution clearance CLd; the
distribution volume in tumour is V2. FNuct in tumour are formed
from 5FU via the metabolic clearance CLm. Population parameters
of 5FU pharmacokinetics in the body and in tumour expressed as
expected value (EV) and inter-individual standard deviations
(iiSD), the typical factor by which EV is multiplied or divided in
diﬀerent individuals, were as follows:
EV iiSD
V1 (L) = 0.117 .BWi/0.215 kg 1.6
CL10 (L/min) = 4.61 · 103 .(BWi/0.215)0.75 1.2
V2 (L) = 4.15 · 103 1.1
CLd (L/min) = 2.93 · 103 7.5
CLm (L/min) = 3.42 · 105 1.6
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V1;i ¼ V1;i eg1 ð3Þ
CL10;i ¼ CL10;i eg2 ð4Þ
where V1,i and CL10,i are the true central distribution
volume and the elimination clearance of animal no. i and
g1, g2 are random variables with mean zero and variance
x1
2 and x2
2, respectively. Inter-individual standard
deviations (iiSD in Table 2) were calculated as ex2.
The residual coeﬃcient of variation was assumed to be
proportional to the square root of the model prediction
(i.e. CV decreases with increasing predicted concentra-
tion):
yij ¼ €yij þp€yij  eij ð5Þ
where yij is the measured concentration in animal no. i at
time j (j=1,. . ., total number of measuring time points in
animal i), y¨ij is the model prediction based on V1,i and
CL10,i, and ij is a random variable with mean zero and
variance x2.
The above model for 5FU kinetics in plasma was
incorporated in a linear three-compartment population
model for 5FU and FNuct in the hepatoma-bearing rats
(Fig. 2, all three boxes). The population parameters
describing 5FU in plasma (V1, CL10, x1
2, x2
2) were kept
ﬁxed as estimated from the rat group where plasma
samples had been taken. The measuring time points for
the NMR data were taken to be the midpoints of the
10 min spectral acquisition periods. The inter-individual
variance model for the tumour parameters was of the
same form as the one for the central compartment
parameters:
V2;i ¼ V2 eg3 ð6Þ
CLd;i ¼ CLd eg4 ð7Þ
CLm;i ¼ CLm eg5 ð8Þ
where V2 is the distribution volume of 5FU in tumour,
CLd is the (bi-directional) distribution clearance of 5FU
between the central compartment and tumour, CLm is
the metabolic clearance governing the conversion of
5FU into FNuct, and g3, g4, g5 are random variables
with mean zero and variances x2, x4
2 and x5
2, respec-
tively. The residual variance model was also the same as
with the plasma data (Eq. 6). After ﬁtting the popula-
tion parameters using NONMEM (see ‘‘Results’’:
Table 2), empirical Bayes estimates of the individual
parameters V1,i, CL10,i, V2,i, CLd,i and CLm,i were
obtained using NONMEM’s POSTHOC function (Note
that keeping the population parameters of central
compartment 5FU kinetics (V1, CLe, x1
2, x2
2) ﬁxed does
not preclude estimating individual gs on V1 and CL10 for
each of the tumour-bearing animals so that each one is
allowed to have its unique set of parameters V1,i, CL10,i,
V2,i, CLd,i, CLm,i describing 5FU pharmacokinetics in
plasma as well as in tumour). The explicit solutions for
the model predictions for compartments 1–3 can be
derived by applying Laplace transformations and the
partial fractions theorem [4, 21]. The result is:
C1 tð Þ ¼ DV1
 
ek10t ð9Þ
A2 tð Þ ¼ Dk12E2  k10
 
ek10t  eE2t  ð10Þ
A3 tð Þ ¼ Dk12k23 e
k10t
E2  k10
 
k30  k10ð Þ
þ eE2t k10  E2ð Þ k30  E2ð Þ
þ ek30t k10  k30ð Þ E2  k30ð Þ ð11Þ
where C1 is 5FU concentration in the central compart-
ment, D is dose, A2 is the amount of 5FU in tumour, A3
is the amount of FNuct in tumour, k10 ¼ CL10=V1,
k12 ¼ CLd=V1, k23 ¼ CLm=V2, E2 ¼ CLd=V2 þ k23, and
k30 is the rate of elimination of FNuct from tumour.
Letting k30 ﬂoat (as opposed to ﬁxing it to zero) pro-
duced no signiﬁcant improvement of ﬁt so that it was
ﬁxed to zero in the ﬁnal ﬁt.
The area under the amount–time curve of 5FU in
tumour from time zero to time inﬁnity was computed
using:
Z1
0
A2 tð Þdt ¼ Dk12E2  k10
1
k10
 1
E2
 
ð12Þ
The total amount of nucleotides formed from time
zero to time inﬁnity is this area multiplied by k23
A3;total ¼ k23 Dk12E2  k10
 
1
k10
 1
E2
 
ð13Þ
Table 2 Summary of parameter estimates in pharmacokinetic model for diﬀerent gas-breathing protocols in H9168a tumours grown in
Buﬀalo rats
Gas V1 (l) V2 (l·103) CL10 (l/min·103) CLd (l/min·103) CLm (l/min·105) t1/25FU (min)
Air (n=5) 0.167±0.051 4.17±0.03 4.08±0.1 2.27±2.72 3.42±2.0 27.6
Carbogen 2a (n=4) 0.131±0.064 4.16±0.08 4.49±0.84 11.53±10.87 4.11±0.8 19.3
Carbogen 2b (n=4) 0.138±0.06 4.11±0.04 5.26±0.35 2.61±1.79 4.02±2.48 20.4
Results show the mean ± SD of estimates of compartment volumes V1 and V2, and the clearance from these compartments from (n)
animals
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Statistics
All data are presented as the mean ± SEM, except
where stated (e.g. Table 2). Estimation of the apparent
rate of elimination of 5FU from GH3 xenografts was
determined from a semi-log plot of peak integral versus
time to provide a t1/2. Statistical analysis utilised a t-test
or a paired t-test where appropriate.
Results
Concentrations of 5FU in rat plasma Table 1 summa-
rises the individual plasma measurements of 5FU made
in eight diﬀerent rats. This data were used in the linear
one-compartment model of plasma pharmacokinetics
(Fig. 2) [(see ‘‘Methods’’)].
Eﬀect of carbogen on 5FU uptake and metabolism in
H9618a hepatomas The uptake and metabolism of
5FU (130 mg/kg) by H9618a tumours in air-breathing
animals is shown in Fig. 3a. The mean 5FU Cmax
determined at 5 min was 631±115 nmoles/g of tu-
mour, which declined with a t1/2 of 31.7±1.5 min and
in most cases remained detectable at 100 min. Metab-
olism to the FNuct was rapid since this signal was
immediately detectable. 5-ﬂuorocatabolites (FCat),
including occasionally very low levels of the ﬁrst
metabolite of catabolism, dihydro-ﬂuorouracil
(DHFU), were also detectable within 10 min and total
catabolite gradually increased throughout the experi-
ment. Tumour uptake and metabolism of 5FU in
carbogen-breathing rats is shown in the accompanying
Fig. 3b,c using the two diﬀerent protocols described in
‘‘Methods’’, and a further analysis of this data is
summarised in Table 3. Although the 5FU Cmax was
unaﬀected, carbogen signiﬁcantly increased the rate of
elimination of 5FU from the tumour (decreased the t1/
2) to 20.7±4.8 min (p=0.007) and 17.9±3.8 min
(p=0.0003) for the protocols 2a and 2b, respectively
(Table 3). The amount of FNuct formed after 100 min
was not signiﬁcantly aﬀected by either protocols, nor
when the carbogen data were pooled (p=0.11). How-
ever, the FNuct AUC was signiﬁcantly increased (by
62%) in protocol 2a, although not in protocol 2b, and
pooling the carbogen data also did not lead to a sig-
niﬁcant eﬀect (p=0.13). Nevertheless, this increase seen
in protocol 2a suggested some impact on FNuct
metabolism, and using the mean 5FU/FNuct AUC
ratio to control for the fact that less 5FU was present
in carbogen-tumours it was apparent that carbogen
signiﬁcantly increased this ratio from 0.55 in air-
breathing animals to 0.89 and 0.80 for carbogen pro-
tocols 2a and 2b, respectively (Table 3). This was sig-
niﬁcant for protocol 2a (p=0.042) and for the pooled
data (p=0.029), but not for 2b (p=0.1). There was no
evidence for a signiﬁcant impact by carbogen on the
presence of the ﬂuorocatabolites.
Fig. 3 Inﬂuence of host carbogen breathing on the uptake and
metabolism of 5FU in H9618a hepatomas grown s.c. in rats. 5FU
was administered as an i.v. bolus of 130 mg/kg/4 ml. Results show
the mean ± SEM from a air-breathing animals (n=5, closed
symbols), b carbogen-breathing animals (n=4) undergoing proto-
col 2a (open symbols) and c carbogen-breathing animals (n=4)
undergoing protocol 2b (open symbols), 5FU (ﬁlled circle), FNuct
(ﬁlled square), FUPA + FBal (ﬁlled down triangle), DHFU (ﬁlled
diamond). From a semi-log plot of the 5FU curve, the t1/2 for
5FU was calculated to be 31.7±1.5 (a), 20.7±4.8 (b) and
17.9±3.8 min (c)
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Pharmacokinetic model Using the one-compartment
model described in ‘‘Methods’’ (Fig. 2), for the indi-
vidual H9168a tumour data, the population parameters
of 5FU kinetics in plasma and tumour and of FNuct
formation in tumour are summarised in Table 2 for air-
breathing and carbogen-breathing rats. The coeﬃcients
of variation of the parameter estimates are 6, 39 and
35% for V2, CLd and CLm, respectively, and are 1,300,
170 and 72% for the corresponding estimates of inter-
individual random variance. Bayesian estimation of
individual parameters resulted in a satisfactory descrip-
tion of the data for 5FU and FNuct formation in tu-
mour in all 13 individual tumours (5 air and 8
carbogens). The period of 5FU entrance into tumour
could be seen in three out of ﬁve air-controls while it was
already over in all carbogen-treated animals at the time
the ﬁrst spectrum was completed (10 min post-injection
of 5FU). The rate of elimination of 5FU from the tu-
mour reﬂected its elimination from plasma in all but one
of the eight carbogen-breathing animals (protocol 2b).
All individual H9168a hepatoma data are summar-
ised in Fig. 4 and Table 2 for air-breathing and carbo-
gen-breathing animals using the two slightly diﬀerent
carbogen protocols 2a and 2b. Both carbogen protocols
tended to decrease the t1/2 for elimination of 5FU from
the tumour (Table 2), conﬁrming the data shown in
Table 3 Summary of eﬀect of carbogen breathing on 5FU uptake and metabolism in H9168a hepatomas grown s.c. in Buﬀalo rats
Gas (n) 5FU t1/2
(min)
5FU Cmax
(nmoles/g)
5FU AUC
(lmoles/g)
FNuct AUC
(lmoles/g)
FNuct,
at 100 min
(nmoles/g)
FCat
AUC
(lmoles/g)
FNuct/5FU
AUC ratio
Air (5) 31.7±1.5 631±115 31.3±4.6 17.3±3.9 248±65 20.8±3.3 0.55±0.13
Crb-2a (4) 20.7±4.8* 788±141 26.8±2.7 23.6±2.5** 313±39 19.4±4.0 0.89±0.1**
Crb-2b (4) 17.9±3.7* 659±184 22.9±4.7 16.9±2.4 255±49 17.7±3.0 0.80±0.12
All Crb (8) 19.3±1.6* 723±110 24.9±2.6 20.2±2.1 284±31 18.6±2.3 0.84±0.07**
Buﬀalo rats bearing H9168a hepatomas breathed either air or
carbogen gas using the protocols described in ‘‘Methods’’ (see also
Fig. 1). Data show mean ± SEM for (n) animals calculated from
the graphs shown in Fig. 3. The 5FU t1/2 was determined from a
semi-log plot of the data and the area under the curve (AUC) was
determined using the trapezoidal rule. Mean values were compared
using Student’s t-test, where *p<0.001 and **p<0.05 signiﬁcantly
signify diﬀerent to air-breathing animals
Fig. 4 Pharmacokinetic
parameters for 5FU in air-
breathing Buﬀalo rats bearing
H9168a hepatomas compared
to two diﬀerent carbogen
breathing protocols. 5FU was
administered as an i.v. bolus of
130 mg/kg/4 ml. g on V1:
individual deviation from the
expected (weight-dependent)
central 5FU distribution
volume as estimated from
plasma samples in a diﬀerent
group of rats. g on CL10: same
for the 5FU elimination
clearance from the central
compartment. V2: 5FU
distribution volume in tumour.
CLd: bi-directional distribution
clearance for 5FU between
central compartment and
tumour. CLm: metabolic
clearance for conversion of
5FU to FNuct in tumour.
Symbols deﬁned as: ﬁlled
square, air breathing; ﬁlled
triangle, carbogen breathing
(protocol 2a); and ﬁlled down
triangle, carbogen breathing
(protocol 2b)
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Table 3. There was a trend for carbogen to decrease the
central 5FU distribution volume, V1 (Fig. 4a) and to
increase clearance of 5FU from the plasma, CL10
(Fig. 4b). The parameter estimates appeared to suggest
that carbogen protocol 2a accelerated the exchange of
5FU between plasma and tumour as indicated by a
raised CLd (Fig. 4c), but it was not possible to ﬁt a
parameter to describe this increase, probably because
5FU entrance into tumour was too rapid to be directly
observable. In three of four animals, carbogen protocol
2b also appeared to increase CLd although to a lesser
extent than protocol 2a (Fig. 4c). Carbogen did not
induce any partitioning of 5FU into tumour, as dem-
onstrated by the lack of an eﬀect on the apparent dis-
tribution volume in tumour, V2 (Fig. 4d). Accordingly,
consistent with the analysis summarised in Table 3, the
tumour 5FU-AUCa remained unchanged, and there was
also no eﬀect on the total amount of FNuct formed
(data not shown). The modelling did not show a clear
trend for the carbogen protocols to increase CLm, i.e.
the rate of FNuct formation (Fig. 4e, Table 2).
Eﬀect of carbogen on 5FU uptake and metabolism in GH3
xenografts 5FU uptake was very variable in these
tumours. The mean Cmax of 801±262 nmoles/g at
10 min (n=5) of air-breathing controls was similar to
that observed in the H9618a hepatomas, the 5FU signal
then decreased with a t1/2
5FU of 19.3±3.8 min and was
rarely detectable after 90 min. FCat were visible imme-
diately and reached values as high as the 5FU Cmax,
while in contrast, the FNuct signal did not appear until
30 min (Fig. 5a). DHFU was never detected. Figure 5
demonstrates that on average, carbogen had very little
eﬀect on 5FU uptake and metabolism in GH3 tumours.
The mean 5FU Cmax of 730±105 nmoles/g of carbogen-
breathing animals was not signiﬁcantly diﬀerent from
controls, although it occurred later at 20 min, and 5FU
then decreased rapidly with a t1/2
5FU of 14.1±1.4 min
(p=0.25 compared to controls). In an attempt to
counter the variability within the model, the areas under
the curves (AUC) shown in Fig. 5 for 5FU and metab-
olites were measured to allow comparisons between
air-breathing and carbogen-breathing animals, but no
signiﬁcant diﬀerences were detected (data not shown). In
addition, the mean FNuct/5FU AUC ratio of 0.3±0.08
was not signiﬁcantly increased compared to the air-
breathing controls of 0.27±0.11. This FNuct/5FU AUC
ratio was ca. half that determined in H9168a hepatomas
(see above) which conﬁrmed that GH3 tumours pro-
duced relatively little FNuct.
As 5FU uptake was very variable between diﬀerent
GH3 xenografts, it was possible that small but biologi-
cally signiﬁcant eﬀects of carbogen on 5FU pharmaco-
kinetics might be masked. To investigate this possibility,
three tumour-bearing animals received a double-dose of
5FU, the second dose given 2 h after the ﬁrst injection,
i.e. about 30 min after the ﬁrst 5FU dose was no longer
detectable by 19F-MRS. In one tumour, the 5FU Cmax
was doubled, and 5FU was then eliminated at the
standard rate. However, in two other GH3 tumours, the
Cmax in air-breathing and carbogen-breathing animals
was the same (results not shown). These experiments
underscored the variability of the GH3 tumour model.
Eﬀects of carbogen on tumour physiology A switch
from air to carbogen breathing rapidly induced an
increase in the normalised GRE-image intensity of both
H9168a (Fig. 6a) and GH3 tumours (Fig. 6b). The
maximum increase was more variable in GH3s than
H9168a, but the mean increase of ca. 60% was similar,
and was sustained as long as the animals breathed
carbogen. On returning to air breathing, the image
intensity decreased slowly so that in both tumour types
it remained signiﬁcantly raised (p<0.05) more than
16 min later.
In GH3 xenografts, carbogen had no eﬀect on the
energy state (ß-NTP/Pi ratio) [(results not shown)], but
signiﬁcantly increased this ratio in H9168a hepatomas,
which was reversed on switching to air breathing
(Table 4). In GH3 xenografts the pH was not measured,
while in the hepatomas, carbogen breathing caused a
signiﬁcant increase in the mean transmembrane negative
Fig. 5 Inﬂuence of host
carbogen breathing on the
uptake and metabolism of 5FU
in s.c. GH3 xenografts. 5FU
was administered as an i.v.
bolus of 130 mg/kg/4 ml.
Results show the mean ± SEM
(n=5) from air-breathing
animals (closed symbols) and
carbogen-breathing animals
(open symbols), 5FU (ﬁlled
circle), FNuct (ﬁlled square),
FUPA + FBal (ﬁlled down
triangle), DHFU (ﬁlled
diamond). From a semi-log plot
of the 5FU curve, the t1/2 for
5FU was calculated to be a
19.3±3.8 min and b
14.1±1.4 min
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pH gradient (DpH) of 0.11 units via a decrease in the
pHe. On switching back to air, the DpH returned to the
pre-treatment value.
Discussion
The results in this paper using two diﬀerent rodent
tumour models show that carbogen breathing can have
profound and varied eﬀects on aspects of tumour
physiology such as energy status, pH and blood ﬂow and
oxygenation (in the guise of FLOOD) which may impact
upon uptake and retention by the tumour of the anti-
cancer drug 5FU. Our analysis suggests that carbogen
can rapidly increase drug uptake from the plasma, but
simultaneously increases drug elimination from the
tumour. Thus, unless there is a secondary mechanism
trapping 5FU in the tumour space, for example a change
in pH or stimulation of 5FU anabolism, carbogen
breathing may not necessarily increase the AUC in tu-
mours.
Breathing of carbogen gas (95% O2, 5% CO2) is
known to have profound eﬀects on both host and
tumour physiology, which include increased O2
dissolved in the blood and host vessel vasoconstriction,
but also increased tumour blood vessel dilation via the
CO2 component [33]. GRE-
1H-imaging has been used to
detect rapid and reversible increases in the image
intensity of some tumours in response to carbogen and
this has been shown in GH3 tumours grown in rats to
reﬂect primarily increases in tumour blood oxygenation
and volume, as well as discrete increases in tumour
blood ﬂow [10, 29, 30]. The eﬀects detected on tumour
blood ﬂow suggested that carbogen could be used to
increase the delivery of chemotherapeutic agents to solid
tumours which can suﬀer from a poor blood supply. We
conﬁrmed this hypothesis in two diﬀerent tumour
models. In GH3 tumours grown in rats, carbogen in-
creased the uptake of i.v. injected ifosfamide but did not
aﬀect the rate of elimination, so that overall drug
retention was increased [31]. In large hypoxic murine
RIF-1 tumours (2–3 g or 7–10% body-weight), carbo-
gen increased the uptake of i.p injected 5FU and reduced
elimination, so that retention and metabolism of 5FU
was markedly increased [19]. However, carbogen had no
signiﬁcant eﬀect on 5FU uptake and metabolism in
small RIF-1 tumours (0.8–1.6 g or 2.5–5%
body-weight). These observations suggest the eﬀects of
carbogen on tumours may not be universal, and indeed
diﬀerent research groups using diﬀerent tumour models
have observed no change as well as both implied and
real increases and decreases in tumour oxygenation,
blood ﬂow, pH and energy status [1, 6, 8, 12, 14, 15, 28,
39]. We decided therefore to investigate the eﬀects of
carbogen on the pharmacokinetics of 5FU in two
additional rodent tumour models, which have shown
signiﬁcant physiological responses to carbogen [29, 35].
The tumour sizes studied were relatively small (i.e. %
Table 4 Eﬀect of carbogen on hepatoma pH and b-NTP/Pi ratios
Time
period
b-NTP/Pi pHi pHe DpH
Before 0.74±0.08 7.17±0.03 6.93±0.05 0.27±0.07
During 1.10±0.09* 7.15±0.02 6.79±0.05** 0.38±0.11**
After 0.83±0.09 7.19±0.03 6.96±0.07 0.26±0.14
Buﬀalo rats bearing H9168a hepatomas breathed air for 24 min
prior to switching to carbogen gas for 20 min and then returning to
air for 16 min. Results show the mean ± SEM from four tumours,
where *p<0.02 and **p<0.01 compared to before carbogen
breathing using a paired t-test
Fig. 6 Eﬀects of carbogen on the GRE-1H-image intensity of
rodent tumours. Nude mice bearing s.c. GH3 tumours and Buﬀalo
rats bearing s.c. H9168a hepatomas breathed air until time zero,
before switching to carbogen gas for 16 min or 20 min (arrow), and
then returning to air breathing. Results show the mean ± SEM
normalised signal intensity from six animals (GH3 xenograft) and
four animals (H9168a hepatomas)
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body-weight was 2–4%), but the hypoxia status was not
determined, and one cannot assume that tumour size
always correlates positively with tumour hypoxia across
all tumour types.
Consistent with previous observations on two diﬀer-
ent rat mammary carcinomas, as well as H9168a hepa-
toma and GH3 prolactinoma in rats or xenografted into
nude mice [28], carbogen breathing immediately induced
a rapid increase in the mean GRE-image intensity to
values ca. 50% greater than baseline. In the experiments
described in this report, images were also acquired after
carbogen breathing was discontinued, and this showed
that the eﬀect was not rapidly reversible as ﬁrst de-
scribed in the GH3 tumour grown in rats [27]. In both
tumour models used in this study, the mean image
intensity remained signiﬁcantly raised 16–20 min after
the switch to air breathing. We have not explored if this
persistent raised image intensity reﬂects increased tu-
mour blood ﬂow or oxygenation or both, although
studies of GH3 tumours in rats showed that a signiﬁcant
proportion of the change in GRE-image intensity could
be due to ﬂow [10]. Thus, although a carbogen-induced
increase in tumour blood ﬂow/blood volume assessed by
GRE-MRI would increase drug delivery, the slow return
to baseline following the return to air breathing may
have allowed an equally rapid elimination of 5FU from
the tumour space, unless some other mechanism trapped
the drug in the tumour. Indeed, this hypothesis is con-
sistent with the lack of signiﬁcant eﬀect of carbogen on
the mean 5FU Cmax at 5–10 min or 5FU AUC in either
of the two tumour models used in this study.
The GH3 xenograft described in this paper appeared
variable in its behaviour with respect to both 5FU
uptake and the maximum change in GRE-MRI image
intensity, and this may have disguised the fact that some
GH3 tumours could respond positively to carbogen in
terms of the 5FU Cmax. As 5FU was eliminated very
quickly from this tumour, it was possible to provide a
second 5FU dose 90 min after the ﬁrst dose, thus
allowing a single tumour to act as its own control. In one
tumour, this experiment clearly demonstrated that
carbogen could increase the 5FU Cmax, but in two other
tumours there was no eﬀect. Thus, on average there was
no signiﬁcant eﬀect of carbogen on the uptake and/or
metabolism of 5FU in the GH3 xenograft.
In Buﬀalo rats, the hosts for the 9618a Hepatoma,
the pharmacokinetic modelling based upon plasma and
19F-MRS data showed that carbogen breathing prior to
5FU injection caused an increase in the 5FU Cmax in
H9168a tumours. Indeed the modelling shows that
carbogen protocol 2a increased the rate of uptake from
plasma to tumour (k12), but also increased the move-
ment in the opposite direction (k21), i.e. CLd increased.
Thus, the simple analysis of mean peak heights could not
detect a signiﬁcant increase in 5FU Cmax. There was a
tendency too for CLm to be raised (20%) suggesting an
acceleration in metabolism of 5FU to FNuct, although
the total FNuct formed was not signiﬁcantly increased.
However, in protocol 2a, the FNuct AUC was signiﬁ-
cantly increased as well as the mean AUC ratio of
FNuct/5FU (which eﬀectively normalises FNuct for-
mation) compared to air breathing, but not for carbogen
protocol 2b. This suggested the longer period of carbo-
gen breathing was not beneﬁcial for FNuct formation,
probably because protocol 2b also signiﬁcantly
increased 5FU elimination from the body (CL10 was
raised). Combining the data for the two carbogen pro-
tocols conﬁrmed a signiﬁcant decrease in the 5FU t1/2
from the tumour and an increase in the FNuct/5FU
AUC ratio. Thus carbogen breathing had some impact
on the rate of FNuct formation which contributed to the
faster disappearance of 5FU from the tumours.
Our analysis underlines two important aspects of the
eﬀects of carbogen. (1) Carbogen can increase elimina-
tion of 5FU from the plasma, presumably through
eﬀects on other tissues besides the tumour; and the
intensity of this eﬀect may be related to the length of
time of carbogen breathing. (2) Carbogen can increase
drug exchange between blood and tumour, although
without a secondary mechanism to trap the drug in the
tumour, e.g. an increase of V2 by partitioning or stim-
ulation of CLm, there will be no net increased retention
of drug. The previous study with RIF-1 tumours showed
that 5FU was only signiﬁcantly retained in large
tumours of 2–3 g, but not smaller tumours of 0.8–1.6 g
[19]. The large tumours were also characterised by (i)
increased retention of a hypoxic marker compared to the
smaller tumours and (ii) a carbogen-induced decrease in
pHe causing an increase in the mean negative pH gra-
dient (DpH). Uptake of 5FU by isolated tumour cells
has been shown to be proportional to the magnitude of
the DpH across the cell plasma membrane [22] and
experiments in vivo have demonstrated that increases in
the DpH are associated with increased retention of
5FU, speciﬁcally an increase in the t1/2 for 5FU elimi-
nation [20]. Changes in the pHe of GH3 xenografts in
response to carbogen were not monitored in this study,
but there was clearly no change in the tumour energy
status (NTP/Pi). However, in H9168a, small but con-
sistent increases in both the DpH (via a decrease in
pHe) and NTP/Pi ratio could be detected. Such eﬀects
might promote both 5FU uptake and metabolism to
FNuct, since the latter is certainly an ATP-dependent
process. Indeed, carbogen had no eﬀect on the FNuct/
5FU ratio in GH3 tumours, but signiﬁcantly increased
this ratio in H9168a tumours. However, unlike in RIF-1
tumours, the pH and energy eﬀects of carbogen were
rapidly reversible, perhaps explaining the lack of any
major eﬀect on overall retention of drug and/or metab-
olites by these tumours.
A study using chemically induced primary rat
mammary tumours demonstrated that initial tumour
NTP/Pi levels were positively and signiﬁcantly corre-
lated with response to 5FU [16]. A similar relationship
was described in RIF-1 tumours [35]. This relationship
may indicate that 5FU readily gains access to well-
perfused tumours, but also that ATP levels can be rate-
limiting in activation of 5FU to FNuct. Therefore, any
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treatment that leads to an increase in the NTP/Pi, such
as increased oxygenation or glucose supply, may aid
tumour sensitivity to 5FU, and the corollary is that
hypoxic regions of tumour would be less sensitive to
5FU. We have shown that carbogen breathing
increases the GRE-image intensity, which would be
consistent with an increase in tumour blood ﬂow, and
thus increased amounts 5FU would be available for
extraction by the tissue. Furthermore, carbogen
breathing has been shown to cause an increase in blood
glucose from liver glycogen breakdown [37], an increase
in tissue pO2 [30] and a decrease in pHe [ref. 19 and
this paper]. Thus, in the case of 5FU, carbogen could
be a principle act on three diﬀerent loci within the
tumour to increase drug uptake and activation: (i)
increased blood ﬂow across the tumour; (ii) a more
acidic pHe with a larger DpH; and (iii) an increase in
the NTP/Pi ratio enhancing FNuct formation. Unfor-
tunately, in the case of the H9168a hepatoma, where all
these eﬀects were demonstrated to occur, (ii) and (iii)
proved too readily reversible, and (i) persisted, which
ultimately allowed greater drug elimination so that
there was little or no improvement in drug retention
and activation. In short, these studies suggest that only
in tumours that are hypoxic, as deﬁned by signiﬁcant
retention of nitroimidazoles and/or a low NTP/Pi ratio,
may carbogen provide clinical beneﬁt by increasing
5FU uptake and retention. This could be tested in a
well-deﬁned hypoxic tumour model such as murine
EMT6 to investigate if hypoxia is the key to carbogen-
induced increases in drug retention.
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